Literature DB >> 22139571

Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines.

Erika da Costa Prando1, Luciane Regina Cavalli, Cláudia Aparecida Rainho.   

Abstract

Epigenetic mechanisms are frequently deregulated in cancer cells and can lead to the silencing of genes with tumor suppressor activities. The isoform A of the Ras-association domain family member 1 (RASSF1A) gene is one of the most frequently silenced transcripts in human tumors, however, few studies have simultaneously investigated epigenetic abnormalities associated with the 3p21.3 tumor suppressor gene cluster flanking RASSF1 (i.e., SEMA3B, HYAL3, HYAL2, HYAL1, TUSC2, RASSF1, ZMYND10, NPRL2, TMEM115, and CACNA2D2). This study aimed to investigate the role of epigenetic changes to these genes in seventeen breast cancer cell lines and in three non-tumorigenic epithelial breast cell lines (184A1, 184B5, and MCF 10A) and to evaluate the effect on gene expression of treatment with the demethylating agent 5-Aza-2'-deoxycytidine and/or Trichostatin A (TSA), a histone deacetylase inhibitor. We report that, although the RASSF1A isoform was determined to be epigenetically silenced in 15 of the 17 breast cancer cell lines, all the cell lines expressed the RASSF1C isoform. Five breast cancer cell lines overexpressed RASSF1C, when compared to the normal epithelial cell line 184A1. Furthermore, the genes HYAL1 and CACNA2D2 were significantly overexpressed after the treatments. After the combinated treatment, RASSF1A re-expression was accompanied by an increase in expression levels of the flanking genes. The Spearman's correlation coefficient indicated a positive co-regulation of the following gene pairs: RASSF1 and TUSC2 (r=0.64, p=0.002), RASSF1 and ZMYND10 (r=0.58, p=0.07), RASSF1 and NPRL2 (r=0.48, p=0.03), ZMYND10 and NPRL2 (r=0.71; p=0,0004), and NPRL2 and TMEM115 (r=0.66, p=0.001). Interestingly, the genes TUSC2, NPRL2 and TMEM115 were found to be unmethylated in each of the untreated cell lines. Chromatin immunoprecipitation using antibodies against the acetylated and trimethylated lysine 9 of histone H3 demonstrated low levels of histone methylation in these genes, which are located closest to RASSF1. These results provide evidence that epigenetic repression is involved in the down-regulation of multiple genes at 3p21.3 in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22139571      PMCID: PMC3256331          DOI: 10.4161/epi.6.12.18271

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  43 in total

1.  Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band.

Authors:  Jordi Frigola; Jenny Song; Clare Stirzaker; Rebecca A Hinshelwood; Miguel A Peinado; Susan J Clark
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

2.  Epigenetic inactivation of the HOXA gene cluster in breast cancer.

Authors:  Petr Novak; Taylor Jensen; Marc M Oshiro; Ryan J Wozniak; Marcella Nouzova; George S Watts; Walter T Klimecki; Christina Kim; Bernard W Futscher
Journal:  Cancer Res       Date:  2006-11-06       Impact factor: 12.701

3.  Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.

Authors:  Masao Ito; Genshi Ito; Masashi Kondo; Mika Uchiyama; Takayuki Fukui; Shoichi Mori; Hiromu Yoshioka; Yuichi Ueda; Kaoru Shimokata; Yoshitaka Sekido
Journal:  Cancer Lett       Date:  2004-12-22       Impact factor: 8.679

4.  Increased hyaluronidase levels in breast tumor metastases.

Authors:  P Bertrand; N Girard; C Duval; J d'Anjou; C Chauzy; J F Ménard; B Delpech
Journal:  Int J Cancer       Date:  1997-11-04       Impact factor: 7.396

5.  The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer.

Authors:  Lishanthi Udabage; Gary R Brownlee; Susan K Nilsson; Tracey J Brown
Journal:  Exp Cell Res       Date:  2005-10-15       Impact factor: 3.905

6.  Regional copy number-independent deregulation of transcription in cancer.

Authors:  Nicolas Stransky; Céline Vallot; Fabien Reyal; Isabelle Bernard-Pierrot; Sixtina Gil Diez de Medina; Rick Segraves; Yann de Rycke; Paul Elvin; Andrew Cassidy; Carolyn Spraggon; Alexander Graham; Jennifer Southgate; Bernard Asselain; Yves Allory; Claude C Abbou; Donna G Albertson; Jean Paul Thiery; Dominique K Chopin; Daniel Pinkel; François Radvanyi
Journal:  Nat Genet       Date:  2006-11-12       Impact factor: 38.330

7.  CACNA2D2-mediated apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and disruption of mitochondria membrane integrity.

Authors:  Giovanni L Carboni; Boning Gao; Masahiko Nishizaki; Kai Xu; John D Minna; Jack A Roth; Lin Ji
Journal:  Oncogene       Date:  2003-01-30       Impact factor: 9.867

Review 8.  3p21.3 tumor suppressor cluster: prospects for translational applications.

Authors:  Lin Ji; John D Minna; Jack A Roth
Journal:  Future Oncol       Date:  2005-02       Impact factor: 3.404

9.  RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma.

Authors:  Lillian Shuk-Nga Chow; Kwok-Wai Lo; Joseph Kwong; Ka-Fai To; Kam-Sze Tsang; Ching-Wan Lam; Reinhard Dammann; Dolly P Huang
Journal:  Int J Cancer       Date:  2004-05-10       Impact factor: 7.396

10.  Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene.

Authors:  Y Sekido; M Ahmadian; I I Wistuba; F Latif; S Bader; M H Wei; F M Duh; A F Gazdar; M I Lerman; J D Minna
Journal:  Oncogene       Date:  1998-06-18       Impact factor: 9.867

View more
  18 in total

Review 1.  Epigenetic alterations in osteosarcoma: promising targets.

Authors:  Binghao Li; Zhaoming Ye
Journal:  Mol Biol Rep       Date:  2014-02-06       Impact factor: 2.316

2.  PHF21B as a candidate tumor suppressor gene in head and neck squamous cell carcinomas.

Authors:  Fernanda Bernardi Bertonha; Mateus de Camargo Barros Filho; Hellen Kuasne; Patricia Pintor Dos Reis; Erika da Costa Prando; Juan José Augusto Moyano Muñoz; Martín Roffé; Glaucia Noeli Maroso Hajj; Luiz Paulo Kowalski; Claudia Aparecida Rainho; Silvia Regina Rogatto
Journal:  Mol Oncol       Date:  2014-10-13       Impact factor: 6.603

3.  CACNA2D2 promotes tumorigenesis by stimulating cell proliferation and angiogenesis.

Authors:  M Warnier; M Roudbaraki; S Derouiche; P Delcourt; A Bokhobza; N Prevarskaya; P Mariot
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

4.  The long non-coding RNA ANRASSF1 in the regulation of alternative protein-coding transcripts RASSF1A and RASSF1C in human breast cancer cells: implications to epigenetic therapy.

Authors:  Naiade Calanca; Ana Paula Paschoal; Érika Prando Munhoz; Layla Testa Galindo; Barbara Mitsuyasu Barbosa; José Roberto Fígaro Caldeira; Rogério Antonio Oliveira; Luciane Regina Cavalli; Silvia Regina Rogatto; Cláudia Aparecida Rainho
Journal:  Epigenetics       Date:  2019-05-27       Impact factor: 4.528

5.  [Detection of DNA methylation of HYAL2 gene for differentiating malignant from benign thyroid tumors].

Authors:  Y Yin; H Li; C Yang; M Zhang; X Huang; M Li; R Yang; Z Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-01-20

6.  Expression and associated epigenetic mechanisms of the Ca2+-signaling genes in breast cancer subtypes and epithelial-to-mesenchymal transition.

Authors:  Andrés Hernández-Oliveras; Ángel Zarain-Herzberg
Journal:  J Cell Commun Signal       Date:  2021-11-11       Impact factor: 5.908

7.  Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma.

Authors:  Asmaa Mosbeh; Khalil Halfawy; Wael S Abdel-Mageed; Dina Sweed; Mohamed H Abdel Rahman
Journal:  Cancer Genet       Date:  2018-04-09

8.  The protein p17 signaling pathways in cancer.

Authors:  Klaus Heese
Journal:  Tumour Biol       Date:  2013-07-31

9.  Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity.

Authors:  Melissa B Davis; Xinyu Liu; Shiyao Wang; Jaxk Reeves; Andrey Khramtsov; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Mol Cancer       Date:  2013-05-10       Impact factor: 27.401

10.  Silencing of RASSF3 by DNA hypermethylation is associated with tumorigenesis in somatotroph adenomas.

Authors:  Hu Peng; Huanhai Liu; Shuwei Zhao; Jian Wu; Jingping Fan; Jianchun Liao
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.